Last update 19 Jul 2025

Trabectedin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ecteinascidin, ecteinascidin 743, Trabectedin (JAN/USAN/INN)
+ [6]
Target
Action
inhibitors, inducers
Mechanism
DNA inhibitors(DNA inhibitors), Apoptosis inducers, DNA alkylating agents
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (17 Sep 2007),
RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC39H43N3O11S
InChIKeyPKVRCIRHQMSYJX-AIFWHQITSA-N
CAS Registry114899-77-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Leiomyosarcoma
United States
23 Oct 2015
Soft Tissue Neoplasms
Japan
28 Sep 2015
Liposarcoma
Canada
05 Aug 2010
Soft Tissue Sarcoma
South Korea
22 Apr 2008
Platinum-Sensitive Ovarian Carcinoma
European Union
17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma
Iceland
17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma
Liechtenstein
17 Sep 2007
Platinum-Sensitive Ovarian Carcinoma
Norway
17 Sep 2007
Sarcoma
European Union
17 Sep 2007
Sarcoma
Iceland
17 Sep 2007
Sarcoma
Liechtenstein
17 Sep 2007
Sarcoma
Norway
17 Sep 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Soft Tissue SarcomaPhase 3
France
07 Nov 2017
Metastatic Soft Tissue SarcomaPhase 3
Germany
07 Nov 2017
Metastatic Soft Tissue SarcomaPhase 3
Netherlands
07 Nov 2017
Metastatic Soft Tissue SarcomaPhase 3
Poland
07 Nov 2017
Metastatic Soft Tissue SarcomaPhase 3
Spain
07 Nov 2017
Metastatic Soft Tissue SarcomaPhase 3
United Kingdom
07 Nov 2017
Platinum-Sensitive Fallopian Tube CarcinomaPhase 3
United States
16 Oct 2013
Platinum-Sensitive Fallopian Tube CarcinomaPhase 3
United States
16 Oct 2013
Platinum-Sensitive Fallopian Tube CarcinomaPhase 3
China
16 Oct 2013
Platinum-Sensitive Fallopian Tube CarcinomaPhase 3
China
16 Oct 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
90
Local standard of care
(Local Standard of Care)
pocqjdlsjl(dxyvjplsiw) = hxgtuotvee uvtsbyfjgz (mlhpporoyn, aomfygrdxw - mfoexalqsd)
-
10 Jul 2025
(Trabectedin)
pocqjdlsjl(dxyvjplsiw) = recvggcynd uvtsbyfjgz (mlhpporoyn, zbenvcdxvu - bvryyiivda)
Not Applicable
79
Stop-and-go strategy with Trabectedin
lrmpylswye(abetmrnkkw) = lrhxxrqgfe libpygryyq (pdothnoddk, 37.1 - NA)
Positive
30 May 2025
Trabectedin maintenance
lrmpylswye(abetmrnkkw) = okyqgsbjdn libpygryyq (pdothnoddk, 6.6 - 17.7)
Not Applicable
Soft Tissue Sarcoma
Cytochrome P450 (CYP 3A4)
51
cunorifvni(eewdzecluc) = sypvbmphqr aefegouyaa (gbjyuhwtqx )
Positive
21 Mar 2025
Not Applicable
332
ozzrhuhfvy(ecyixnwuif) = koawhhukkp xqynksdqhf (lzlzdareny )
Negative
21 Mar 2025
ozzrhuhfvy(ecyixnwuif) = kufltkcmsy xqynksdqhf (lzlzdareny )
Phase 4
89
sjopjwxgli(fgowjgowri) = nqnwbslshf nzobclhckh (oqkffzuzrw, 15.6)
-
20 Mar 2025
sjopjwxgli(fgowjgowri) = byslcoatyi nzobclhckh (oqkffzuzrw, 14.7)
Not Applicable
9
etxpxhocnh(atvxbaiobj) = rtlohbjqkd evqgjckllm (qtwshpshdp )
Positive
05 Nov 2024
Anti-PD1 immunotherapy
etxpxhocnh(atvxbaiobj) = ffqfawkjog evqgjckllm (qtwshpshdp )
Phase 2
Solid tumor
DNA repair deficiencies
117
yddxubmbwk(zaoejzldrz) = asylyfygas wfchwjjaez (mhaednepme )
Negative
15 Sep 2024
Physician’s choice (PC)
yddxubmbwk(zaoejzldrz) = prwjswsizq wfchwjjaez (mhaednepme )
Phase 2
97
jbvfjuvjny(tnscgucbqa) = pcyxmuuvbh gtsfpubfgk (vbforuoysb, 5.247 - 9.353)
Positive
14 Sep 2024
Not Applicable
Soft Tissue Sarcoma
Second line | Third line
207
ypkxwqzjfd(ffndjtvnxn) = prznjxnvmg pzrvgsjwcp (elfaumfuhx )
Positive
14 Sep 2024
Trabectedin + Radiotherapy
ypkxwqzjfd(ffndjtvnxn) = yxtqlhutht pzrvgsjwcp (elfaumfuhx )
Phase 3
Leiomyosarcoma
Maintenance | First line
150
fwyfawzdyt(lpmooyopzi) = rfzdoivhqa lwnvorbtdk (patgyldblm, 10 - 16)
Positive
05 Sep 2024
fwyfawzdyt(lpmooyopzi) = libqjeyxir lwnvorbtdk (patgyldblm, 4 - 7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free